The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies

International Journal of Cell Biology

Volumn , Issue , 2010, Pages

  Diederich, Marc ^a   Sobolewski, Cyril ^a   Cerella, Claudia ^a   Dicato, Mario ^a   Ghibelli, Lina ^b  

^a HÔpital Kirchberg   (Luxembourg)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CAY 10404; CELECOXIB; CHLORAMBUCIL; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GEMCITABINE; IBUPROFEN; INDOMETACIN; L 161982; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOTOFRIN; PIROXICAM; ROFECOXIB; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOIKIS; APOPTOSIS; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CELL PROLIFERATION; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FAMILIAL COLON POLYPOSIS; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR;

EID: 77955939152     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2010/215158     Document Type: Review

References (172)

1. Kulinsky V. I., Biochemical aspects of inflammation Biochemistry 2007 72 6 595 607
2. DuBois R. N., Abramson S. B., Crofford L., Cyclooxygenase in biology and disease FASEB Journal 1998 12 12 1063 1073
3. Balkwill F., Mantovani A., Inflammation and cancer: back to Virchow? The Lancet 2001 357 9255 539 545
4. Dennis L. K., Lynch C. F., Torner J. C., Epidemiologic association between prostatitis and prostate cancer Urology 2002 60 1 78 83
5. Howe L. R., Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer Breast Cancer Research 2007 9 4 210
6. Coussens L. M., Werb Z., Inflammation and cancer Nature 2002 420 6917 860 867
7. Suganuma M., Okabe S., Marino M. W., Sakai A., Sueoka E., Fujiki H., Essential role of tumor necrosis factor (TNF- ) in tumor promotion as revealed by TNF- -deficient mice Cancer Research 1999 59 18 4516 4518
8. Yao M., Lam E. C., Kelly C. R., Zhou W., Wolfe M. M., Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer British Journal of Cancer 2004 90 3 712 719
9. DuBois R. N., Smalley W. E., Cyclooxygenase, NSAIDs, and colorectal cancer Journal of Gastroenterology 1996 31 6 898 906
10. Eisinger A. L., Prescott S. M., Jones D. A., Stafforini D. M., The role of cyclooxygenase-2 and prostaglandins in colon cancer Prostaglandins and Other Lipid Mediators 2007 82 14 147 154
11. Steinbach G., Lynch P. M., Phillips R. K. S., The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis The New England Journal of Medicine 2000 342 26 1946 1952
12. Hussain S. P., Harris C. C., Inflammation and cancer: an ancient link with novel potentials International Journal of Cancer 2007 121 11 2373 2380
13. Cristofanon S., Morceau F., Scovassi A. I., Dicato M., Ghibelli L., Diederich M., Oxidative, multistep activation of the noncanonical NF- B pathway via disulfide Bcl-3/p50 complex FASEB Journal 2009 23 45 57
14. Chen R., Alvero A. B., Silasi D. A., Mor G., Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway American Journal of Reproductive Immunology 2007 57 2 93 107
15. DAlessio M., Cerella C., Amici C., Glutathione depletion up-regulates Bcl-2 in BSO-resistant cells FASEB Journal 2004 18 13 1609 1611
16. Lin W. W., Karin M., A cytokine-mediated link between innate immunity, inflammation, and cancer Journal of Clinical Investigation 2007 117 5 1175 1183
17. Pikarsky E., Porat R. M., Stein I., NF- B functions as a tumour promoter in inflammation-associated cancer Nature 2004 431 7007 461 466
18. Palayoor S. T., Youmell M. Y., Calderwood S. K., Coleman C. N., Price B. D., Constitutive activation of I B kinase and NF- B in prostate cancer cells is inhibited by ibuprofen Oncogene 1999 18 51 7389 7394
19. Kordes U., Krappmann D., Heissmeyer V., Ludwig W. D., Scheidereit C., Transcription factor NF- B is constitutively activated in acute lymphoblastic leukemia cells Leukemia 2000 14 3 399 402
20. Tricot G., New insights into role of microenvironment in multiple myeloma The Lancet 2000 355 9200 248 250
21. Chandrasekharan N. V., Simmons D. L., The cyclooxygenases Genome Biology 2004 5 9, article 241
22. Narumiya S., FitzGerald G. A., Genetic and pharmacological analysis of prostanoid receptor function Journal of Clinical Investigation 2001 108 1 25 30
23. Ramsay R. G., Ciznadija D., Vanevski M., Mantamadiotis T., Transcriptional regulation of cyclo-oxygenase expression: three pillars of control International Journal of Immunopathology and Pharmacology 2003 16 2, supplement 59 67
24. Hinz B., Brune K., Cyclooxygenase-210 years later Journal of Pharmacology and Experimental Therapeutics 2002 300 2 367 375
25. Kurumbail R. G., Stevens A. M., Gierse J. K., Structural basis for selective inhibition of cyciooxygenase-2 by anti-inflammatory agents Nature 1996 384 6610 644 648
26. Sarkar F. H., Adsule S., Li Y., Padhye S., Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy Mini-Reviews in Medicinal Chemistry 2007 7 6 599 608
27. Kis B., Snipes J. A., Isse T., Nagy K., Busija D. W., Putative cyclooxygenase-3 expression in rat brain cells Journal of Cerebral Blood Flow and Metabolism 2003 23 11 1287 1292
28. Chandrasekharan N. V., Dai H., Roos K. L. T., COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression Proceedings of the National Academy of Sciences of the United States of America 2002 99 21 13926 13931
29. Hinz B., Cheremina O., Brune K., Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man FASEB Journal 2008 22 2 383 390
30. Cao Y., Prescott S. M., Many actions of cyclooxygenase-2 in cellular dynamics and in cancer Journal of Cellular Physiology 2002 190 3 279 286
31. Ristimaki A., Sivula A., Lundin J., Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer Cancer Research 2002 62 3 632 635
32. Secchiero P., Barbarotto E., Gonelli A., Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells American Journal of Pathology 2005 167 6 1599 1607
33. Nakanishi Y., Kamijo R., Takizawa K., Hatori M., Nagumo M., Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines European Journal of Cancer 2001 37 12 1570 1578
34. Wun T., McKnight H., Tuscano J. M., Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma Leukemia Research 2004 28 2 179 190
35. Chan M. W., Wong C. Y., Cheng A. S., Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells Oncology Reports 2007 18 6 1557 1562
36. Johnson G. E., Ivanov V. N., Hei T. K., Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival Apoptosis 2008 13 6 790 802
37. Palayoor S. T., Arayankalayil M. J., Shoaibi A., Coleman C. N., Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2 Clinical Cancer Research 2005 11 19 6980 6986
38. Philip M., Rowley D. A., Schreiber H., Inflammation as a tumor promoter in cancer induction Seminars in Cancer Biology 2004 14 6 433 439
39. Zrieki A., Farinotti R., Buyse M., Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal caco-2 cell line Pharmaceutical Research 2008 25 9 1991 2001
40. Choi E. M., Kwak S. J., Kim Y. M., COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells Experimental and Molecular Medicine 2005 37 3 199 203
41. Breyer R. M., Bagdassarian C. K., Myers S. A., Breyer M. D., Prostanoid receptors: subtypes and signaling Annual Review of Pharmacology and Toxicology 2001 41 661 690
42. Grossmann J., Molecular mechanisms of detachment-induced apoptosisanoikis Apoptosis 2002 7 3 247 260
43. Woodgett J. R., Regulation and functions of the glycogen synthase kinase-3 subfamily Seminars in Cancer Biology 1994 5 4 269 275
44. Boughton Smith N. K., Hawkey C. J., Whittle B. J. R., Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa Gut 1983 24 12 1176 1182
45. Yang V. W., Shields J. M., Hamilton S. R., Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis Cancer Research 1998 58 8 1750 1753
46. Sheng H., Shao J., Morrow J. D., Beauchamp R. D., DuBois R. N., Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells Cancer Research 1998 58 2 362 366
47. Doherty G. A., Byrne S. M., Molloy E. S., Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer BMC Cancer 2009 9, article 207
48. Damstrup L., Kuwada S. K., Dempsey P. J., Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis British Journal of Cancer 1999 80 7 1012 1019
49. She Q. B., Solit D. B., Ye Q., OReilly K. E., Lobo J., Rosen N., The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells Cancer Cell 2005 8 4 287 297
50. Tessner T. G., Muhale F., Riehl T. E., Anant S., Stenson W. F., Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and Bax translocation Journal of Clinical Investigation 2004 114 11 1676 1685
51. Burlacu A., Regulation of apoptosis by Bcl-2 family proteins Journal of Cellular and Molecular Medicine 2003 7 3 249 257
52. Yamaki T., Endoh K., Miyahara M., Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3 Cancer Letters 2004 214 1 115 120
53. Billen L. P., Kokoski C. L., Lovell J. F., Leber B., Andrews D. W., Bcl-XL inhibits membrane permeabilization by competing with Bax PLoS Biology 2008 6 6, article e147
54. Stewart Z. A., Westfall M. D., Pietenpol J. A., Cell-cycle dysregulation and anticancer therapy Trends in Pharmacological Sciences 2003 24 3 139 145
55. Larrea M. D., Liang J., Da Silva T., Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4 Molecular and Cellular Biology 2008 28 20 6462 6472
56. Pagano M., Tam S. W., Theodoras A. M., Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 Science 1995 269 5224 682 685
57. Bos J. L., ras Oncogenes in human cancer: a review Cancer Research 1989 49 17 4682 4689
58. Tsatsanis C., Androulidaki A., Venihaki M., Margioris A. N., Signalling networks regulating cyclooxygenase-2 International Journal of Biochemistry and Cell Biology 2006 38 10 1654 1661
59. Yano T., Zissel G., Muller-Qernheim J., Jae Shin S., Satoh H., Ichikawa T., Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3 FEBS Letters 2002 518 13 154 158
60. Junttila M. R., Westermarck J., Mechanisms of MYC stabilization in human malignancies Cell Cycle 2008 7 5 592 596
61. Ma X., Kundu N., Rifat S., Walser T., Fulton A. M., Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis Cancer Research 2006 66 6 2923 2927
62. Majima M., Hayashi I., Muramatsu M., Katada J., Yamashina S., Katori M., Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants British Journal of Pharmacology 2000 130 3 641 649
63. Folkman J., Tumor angiogenesis: therapeutic implications The New England Journal of Medicine 1971 285 21 1182 1186
64. Green G. A., Understanding NSAIDs: from aspirin to COX-2 Clinical Cornerstone 2001 3 5 50 59
65. Ferreira S. H., Moncada S., Vane J. R., Indomethacin and aspirin abolish prostaglandin release from the spleen Nature 1971 231 25 237 239
66. Pasa S., Bayan K., Kucukoner M., The effects of nonsteroidal anti-inflammatory drugs on platelet function and severity of upper gastrointestinal haemorrhage Journal of Thrombosis and Thrombolysis 2009 28 1 83 89
67. Hudson M., Rahme E., Richard H., Pilote L., Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Care and Research 2007 57 3 516 523
68. Grosch S., Maier T. J., Schiffmann S., Geisslinger G., Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors Journal of the National Cancer Institute 2006 98 11 736 747
69. White W. B., Faich G., Whelton A., Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac American Journal of Cardiology 2002 89 4 425 430
70. Farkouh M. E., Verheugt F. W. A., Ruland S., A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen Journal of Clinical Hypertension 2008 10 8 592 602
71. Whelton A., Fort J. G., Puma J. A., Normandin D., Bello A. E., Verburg K. M., Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients American Journal of Therapeutics 2001 8 2 85 95
72. Juhlin T., Bjrkman S., Hglund P., Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors European Journal of Heart Failure 2005 7 6 1049 1056
73. Zhao S. Z., Reynolds M. W., Lefkowith J., Whelton A., Arellano F. M., A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database Clinical Therapeutics 2001 23 9 1478 1491
74. van Staa T. P., Smeeth L., Persson I., Parkinson J., Leufkens H. G. M., What is the harmbenefit ratio of Cox-2 inhibitors? International Journal of Epidemiology 2008 37 2 405 413
75. De Smet B. D., Fendrick A. M., Stevenson J. G., Bernstein S. J., Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited Journal of General Internal Medicine 2006 21 7 694 697
76. Strillacci A., Griffoni C., Spisni E., Manara M. C., Tomasi V., RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells British Journal of Cancer 2006 94 9 1300 1310
77. Peng H. L., Zhang G. S., Liu J. H., Gong F. J., Li R. J., Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation Annals of Hematology 2008 87 2 121 129
78. Sheng H., Shao J., Kirkland S. C., Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 Journal of Clinical Investigation 1997 99 9 2254 2259
79. Amano H., Hayashi I., Endo H., Host prostaglandin E2 -EP3 signaling regulates tumor-associated angiogenesis and tumor growth Journal of Experimental Medicine 2003 197 2 221 232
80. Hochegger H., Takeda S., Hunt T., Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nature Reviews Molecular Cell Biology 2008 9 11 910 916
81. Cobrinik D., Pocket proteins and cell cycle control Oncogene 2005 24 17 2796 2809
82. Kelman Z., PCNA: structure, functions and interactions Oncogene 1997 14 6 629 640
83. Taylor W. R., Stark G. R., Regulation of the G2/M transition by p53 Oncogene 2001 20 15 1803 1815
84. Li J., Chen X., Dong X., Xu Z., Jiang H., Sun X., Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells Journal of Gastroenterology and Hepatology 2006 21 12 1814 1820
85. Castellone M. D., Teramoto H., Williams B. O., Druey K. M., Gutkind J. S., Prostaglandin E2 promotes colon cancer cell growth through a Gs -axin- -catenin signaling axis Science 2005 310 5753 1504 1510
86. Xin B., Yokoyama Y., Shigeto T., Mizunuma H., Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers Pathology and Oncology Research 2007 13 4 365 369
87. Falandry C., Canney P. A., Freyer G., Dirix L. Y., Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer Annals of Oncology 2009 20 4 615 620
88. Xu X. F., Xie C. G., Wang X. P., Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo Tohoku Journal of Experimental Medicine 2008 215 2 149 157
89. Zhang G. S., Liu D. S., Dai C. W., Li R. J., Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib American Journal of Hematology 2006 81 4 242 255
90. Dimmeler S., Breitschopf K., Haendeler J., Zeiher A. M., Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway Journal of Experimental Medicine 1999 189 11 1815 1822
91. Majno G., Joris I., Apoptosis, oncosis, and necrosis: an overview of cell death American Journal of Pathology 1995 146 1 3 15
92. Fullard J. F., Kale A., Baker N. E., Clearance of apoptotic corpses Apoptosis 2009 14 8 1029 1037
93. Shimohama S., Apoptosis in Alzheimers diseasean update Apoptosis 2000 5 1 9 16
94. Coppola S., Ghibelli L., GSH extrusion and the mitochondrial pathway of apoptotic signalling Biochemical Society Transactions 2000 28 2 56 61
95. Henshall D. C., Bonislawski D. P., Skradski S. L., Lan J. Q., Meller R., Simon R. P., Cleavage of bid may amplify caspase-8-induced neuronal death following focally evoked limbic seizures Neurobiology of Disease 2001 8 4 568 580
96. Cha Y. J., Kim H. S., Rhim H., Kim B. E., Jeong S. W., Kim I. K., Activation of caspase-8 in 3-deazaadenosine-induced apoptosis of U-937 cells occurs downstream of caspase-3 and caspase-9 without Fas receptor-ligand interaction Experimental and Molecular Medicine 2001 33 4 284 292
97. Ghibelli L., Fanelli C., Rotilio G., Rescue of cells from apoptosis by inhibition of active GSH extrusion FASEB Journal 1998 12 6 479 486
98. DAlessio M., De Nicola M., Coppola S., Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis FASEB Journal 2005 19 11 1504 1506
99. Zhou L., Chang D. C., Dynamics and structure of the Bax-Bak complex responsible for releasing mitochondrial proteins during apoptosis Journal of Cell Science 2008 121 13 2186 2196
100. Tamm I., Wang Y., Sausville E., IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs Cancer Research 1998 58 23 5315 5320
101. Chai J., Du C., Wu J. W., Kyin S., Wang X., Shi Y., Structural and biochemical basis of apoptotic activation by Smac/DIABLO Nature 2000 406 6798 855 862 (Pubitemid 30664254)
102. Liu X. H., Yao S., Kirschenbaum A., Levine A. C., NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates Bcl-2 expression in LNCaP cells Cancer Research 1998 58 19 4245 4249
103. Cao Y., Pearman A. T., Zimmerman G. A., McIntyre T. M., Prescott S. M., Intracellular unesterified arachidonic acid signals apoptosis Proceedings of the National Academy of Sciences of the United States of America 2000 97 21 11280 11285
104. Jayadev S., Linardic C. M., Hannun Y. A., Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor The Journal of Biological Chemistry 1994 269 8 5757 5763
105. Pettus B. J., Chalfant C. E., Hannun Y. A., Ceramide in apoptosis: an overview and current perspectives Biochimica et Biophysica Acta 2002 1585 2-3 114 125
106. Chan T. A., Morin P. J., Vogelstein B., Kinzler K. W., Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis Proceedings of the National Academy of Sciences of the United States of America 1998 95 2 681 686
107. Brne B., von Knethen A., Sandau K. B., Nitric oxide (NO): an effector of apoptosis Cell Death and Differentiation 1999 6 10 969 975
108. Chang Y. W. E., Jakobi R., McGinty A., Foschi M., Dunn M. J., Sorokin A., Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity Molecular and Cellular Biology 2000 20 22 8571 8579
109. Lau L. M. S., Wolter J. K., Lau J. T. M. L., Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma Oncogene 2009 28 19 2024 2033
110. Irwin M. S., Miller F. D., p73: regulator in cancer and neural development Cell Death and Differentiation 2004 11 supplement 1 S17 S22
111. Kim N., Kim C. H., Ahn D. W., Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling Journal of Gastroenterology and Hepatology 2009 24 3 480 487
112. Liu B., Shi Z. l., Feng J., Tao H. M., Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt Cell Biology International 2008 32 5 494 501
113. Hsu A. L., Ching T. T., Wang D. S., Song X., Rangnekar V. M., Chen C. S., The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 The Journal of Biological Chemistry 2000 275 15 11397 11403
114. Honjo S., Osaki M., Ardyanto T. D., Hiramatsu T., Maeta N., Ito H., COX-2 inhibitor, NS398, enhances fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines DNA and Cell Biology 2005 24 3 141 147
115. Liou J. Y., Ghelani D., Yeh S., Wu K. K., Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3 Cancer Research 2007 67 7 3185 3191
116. Yamamoto Y., Yin M. J., Lin K. M., Gaynor R. B., Sulindac inhibits activation of the NF- B pathway The Journal of Biological Chemistry 1999 274 38 27307 27314
117. Poligone B., Baldwin A. S., Positive and negative regulation of NF- B by COX-2: roles of different prostaglandins The Journal of Biological Chemistry 2001 276 42 38658 38664
118. Park M. K., Kang Y. J., Ha Y. M., EP 2 receptor activation by prostaglandin E2 leads to induction of HO-1 via PKA and PI3K pathways in C6 cells Biochemical and Biophysical Research Communications 2009 379 4 1043 1047
119. Martin S., Phillips D. C., Szekely-Szucs K., Elghazi L., Desmots F., Houghton J. A., Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae Cancer Research 2005 65 24 11447 11458
120. Tang R., Faussat A.-M., Perrot J.-Y., Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML) BMC Cancer 2008 8, article 51
121. Yamanaka Y., Shiraki K., Inoue T., COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis International Journal of Molecular Medicine 2006 18 1 41 47
122. Casado M., Molla B., Roy R., Protection against Fas-induced liver apoptosis in transgenic mice expressing cyclooxygenase 2 in hepatocytes Hepatology 2007 45 3 631 638
123. Nzeako U. C., Guicciardi M. E., Yoon J. H., Bronk S. F., Gores G. J., COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells Hepatology 2002 35 3 552 559
124. Frisch S. M., Ruoslahti E., Integrins and anoikis Current Opinion in Cell Biology 1997 9 5 701 706
125. Giancotti F. G., Ruoslahti E., Integrin signaling Science 1999 285 5430 1028 1032
126. Joseph R. R., Yazer E., Hanakawa Y., Stadnyk A. W., Prostaglandins and activation of AC/cAMP prevents anoikis in IEC-18 Apoptosis 2005 10 6 1221 1233
127. Kanayama S., Yamada Y., Kawaguchi R., Tsuji Y., Haruta S., Kobayashi H., Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells Oncology Reports 2008 19 1 117 122
128. Beviglia L., Matsumoto K., Lin C. S., Ziober B. L., Kramer R. H., Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression International Journal of Cancer 1997 74 3 301 309
129. Dong G., Chen Z., Li Z. Y., Yeh N. T., Bancroft C. C., Van Waes C., Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma Cancer Research 2001 61 15 5911 5918
130. Wagatsuma S., Konno R., Sato S., Yajima A., Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma Cancer 1998 82 3 520 530
131. Zeng Q., McCauley L. K., Wang C. Y., Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2: implication in head and neck squamous cell carcinoma progression The Journal of Biological Chemistry 2002 277 51 50137 50142 (Pubitemid 36014467)
132. Maiuri M. C., Zalckvar E., Kimchi A., Kroemer G., Self-eating and self-killing: crosstalk between autophagy and apoptosis Nature Reviews Molecular Cell Biology 2007 8 9 741 752
133. Bauvy C., Gane P., Arico S., Codogno P., Ogier-Denis E., Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29 Experimental Cell Research 2001 268 2 139 149
134. Lynch P. M., COX-2 inhibition in clinical cancer prevention Oncology 2001 15 3, supplement 5 21 26
135. Arber N., Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point Cancer Epidemiology Biomarkers and Prevention 2008 17 8 1852 1857
136. Arun B., Goss P., The role of COX-2 inhibition in breast cancer treatment and prevention Seminars in Oncology 2004 31 supplement 7 22 29
137. Bell D. W., Varley J. M., Szydlo T. E., Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome Science 1999 286 5449 2528 2531
138. Grimes K. R., Warren G. W., Fang F., Xu Y., St Clair W. H., Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo Oncology Reports 2006 16 4 771 776
139. Czembirek C., Eder-Czembirek C., Erovic B. M., The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells Strahlentherapie und Onkologie 2009 185 5 310 317
140. Chabner B. A., Roberts T. G. Jr., Chemotherapy and the war on cancer Nature Reviews Cancer 2005 5 1 65 72
141. Luqmani Y. A., Mechanisms of drug resistance in cancer chemotherapy Medical Principles and Practice 2005 14 supplement 1 35 48
142. Puhlmann U., Ziemann C., Ruedell G., Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells Journal of Pharmacology and Experimental Therapeutics 2005 312 1 346 354
143. Patel V. A., Dunn M. J., Sorokin A., Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2 The Journal of Biological Chemistry 2002 277 41 38915 38920
144. Chen X. J., Xiao W., Qu X., Zhou S. Y., NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein Neoplasma 2008 55 3 200 204
145. Dougherty T. J., An update on photodynamic therapy applications Journal of Clinical Laser Medicine and Surgery 2002 20 1 3 7
146. Dolmans D. E., Fukumura D., Jain R. K., Photodynamic therapy for cancer Nature Reviews Cancer 2003 3 5 380 387
147. Dougherty T. J., Gomer C. J., Henderson B. W., Photodynamic therapy Journal of the National Cancer Institute 1998 90 889 905
148. Ferrario A., Fisher A. M., Rucker N., Gomer C. J., Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors Cancer Research 2005 65 20 9473 9478
149. Ferrario A., Von Tiehl K., Wong S., Luna M., Gomer C. J., Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response Cancer Research 2002 62 14 3956 3961
150. Hendrickx N., Volanti C., Moens U., Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells The Journal of Biological Chemistry 2003 278 52 52231 52239
151. Lasa M., Mahtani K. R., Finch A., Brewer G., Saklatvala J., Clark A. R., Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade Molecular and Cellular Biology 2000 20 12 4265 4274
152. Makowski M., Grzela T., Niderla J., Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice Clinical Cancer Research 2003 9 14 5417 5422
153. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R. N., Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 1998 93 5 705 716
154. Bhui K., Prasad S., George J., Shukla Y., Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway Cancer Letters 2009 282 2 167 176
155. Kalra N., Bhui K., Roy P., Regulation of p53, nuclear factor B and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin Toxicology and Applied Pharmacology 2008 226 1 30 37
156. Singh M., Singh N., Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells Molecular and Cellular Biochemistry 2009 325 1-2 107 119
157. Marn Y. E., Wall B. A., Wang S., Curcumin downregulates the constitutive activity of NF- B and induces apoptosis in novel mouse melanoma cells Melanoma Research 2007 17 5 274 283
158. Park C., Moon D. O., Choi I. W., Curcumin induces apoptosis and inhibits prostaglandin E2 production in synovial fibroblasts of patients with rheumatoid arthritis International Journal of Molecular Medicine 2007 20 3 365 372
159. Weber W. M., Hunsaker L. A., Gonzales A. M., TPA-induced up-regulation of activator protein-1 can be inhibited or enhanced by analogs of the natural product curcumin Biochemical Pharmacology 2006 72 8 928 940
160. Goel A., Prasad A. K., Parmar V. S., Ghosh B., Saini N., Apoptogenic effect of 7,8-diacetoxy-4-methylcoumarin and 7,8-diacetoxy-4-methylthiocoumarin in human lung adenocarcinoma cell line: role of NF- B, Akt, ROS and MAP kinase pathway Chemico-Biological Interactions 2009 179 2-3 363 374
161. Suh Y., Afaq F., Johnson J. J., Mukhtar H., A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF- B-signaling pathways Carcinogenesis 2009 30 2 300 307
162. Moon D. O., Kim M. O., Kang S. H., Choi Y. H., Kim G. Y., Sulforaphane suppresses TNF- -mediated activation of NF- B and induces apoptosis through activation of reactive oxygen species-dependent caspase-3 Cancer Letters 2009 274 1 132 142
163. Nam S. Y., Kim J. S., Kim J. M., DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis Experimental Biology and Medicine 2008 233 2 180 191
164. Harper C. E., Patel B. B., Wang J., Eltoum I. A., Lamartiniere C. A., Epigallocatechin-3-gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action Prostate 2007 67 14 1576 1589
165. Adhami V. M., Malik A., Zaman N., Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo Clinical Cancer Research 2007 13 5 1611 1619
166. Pandey M. K., Sandur S. K., Sung B., Sethi G., Kunnumakkara A. B., Aggarwal B. B., Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)- B and NF- B-regulated gene expression through direct inhibition of I B kinase on cysteine 179 residue The Journal of Biological Chemistry 2007 282 24 17340 17350
167. Hostanska K., Jurgenliemk G., Abel G., Nahrstedt A., Saller R., Willow bark extract (BNO1455) and its fractions suppress growth and induce apoptosis in human colon and lung cancer cells Cancer Detection and Prevention 2007 31 2 129 139
168. Liang J., Slingerland J. M., Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression Cell Cycle 2003 2 4 339 345
169. Rssig L., Jadidi A. S., Urbich C., Badorff C., Zeiher A. M., Dimmeler S., Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation of endothelial cells Molecular and Cellular Biology 2001 21 16 5644 5657
170. Totzke G., Schulze-Osthoff K., Jnicke R. U., Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition Oncogene 2003 22 39 8021 8030
171. Ryan E. P., Bushnell T. P., Friedman A. E., Rahman I., Phipps R. P., Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells Cancer Immunology, Immunotherapy 2008 57 3 347 358
172. Mutter R., Lu B., Carbone D. P., A Phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer Clinical Cancer Research 2009 15 6 2158 2165